GSK Bolsters its Electroceutical Position with $50M Investment
By Nuala Moran
Wednesday, August 14, 2013
LONDON Glaxosmithkline plc (GSK) has put further flesh on its ambition to become a leader in electroceuticals in which nanoscale devices will be used to modulate the body's neural circuits with the announcement of a $50 million venture capital fund to back pioneers in the field.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.